Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Mar 2;12:559–569. doi: 10.2147/NDT.S98511

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 Petrò et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Changes in pain intensity scores during treatment with prolonged-release oxycodone/naloxone (OXN-PR).

Notes: (A) Pain assessed using a numerical rating scale (NRS) (n=30); P<0.001 for T7 versus T0, T15 versus T7, and T45 versus T15. (B) Pain assessed using the Pain Assessment in Advanced Dementia (PAINAD) questionnaire in patients whose pain could not be assessed using the NRS (n=23, see text for further explanations); P<0.001 for T7 versus T0, and T15 versus T7; P<0.01 for T45 versus T15. T0, baseline (OXN-PR initiation); T7, T15, T45, respectively, 7-, 15-, and 45 days after beginning of OXN-PR treatment.